Viking Therapeutics, Inc. (vktx)
VKTX Estimates
Public analyst price targets and consensus snapshot for Viking Therapeutics, Inc.. Deeper estimate history and models are available in Vest Terminal.
| Last price | $41.65 |
| Analyst mean target | $94.82 |
| Analyst high target | $125.00 |
| Analyst low target | $38.00 |
| Upside vs mean target | 127.6% |
| Consensus recommendation | Strong Buy |
| Number of analysts | 19 |
| Forward P/E | -9.46 |
Start Free — open VKTX in Vest Terminal
Access live data, filings, ownership, and analysis for Viking Therapeutics, Inc..
Viking Therapeutics, Inc. FAQ
What does Viking Therapeutics, Inc. (VKTX) do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone…
What is VKTX's P/E ratio?
Viking Therapeutics, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does VKTX pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is VKTX in?
Viking Therapeutics, Inc. is classified in Healthcare (Biotechnology) on NCM.
What is VKTX's market capitalization?
Approximate market cap: $4.86B.
What are the main risks for VKTX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of VKTX?
Potential positives include moderate leverage (debt/equity 1.00), price near 52-week highs — positive price momentum on public markets.
Where can I get analyst estimates for VKTX?
Public analyst price targets and consensus for Viking Therapeutics, Inc. are on the free /stocks/vktx/estimates page. Deeper estimate history and models are available in Vest Terminal.